Polypharmacy and drug-drug interactions in older and younger people living with HIV: The POPPY study

Marie O. Halloran, Catherine Boyle, Emmanouil Bagkeris, Paddy Mallon, Frank A. Post, Jamie Vera, Ian Williams, Jane Anderson, Alan Winston, Memory Sachikonye, Caroline Sabin, Marta Boffito

Research output: Contribution to journalArticlepeer-review

22 Citations (Scopus)

Abstract

Background: Polypharmacy (use of ≥ five medications) increases the risk of drug-drug interactions and can lead to negative health outcomes. This study aimed to review the medications of people living with HIV (PLWH) and HIV-negative controls in the POPPY study and evaluate the frequency of polypharmacy and potential drug-drug interactions (PDDIs). Methods: PDDIs between non-antiretroviral (ARV) drugs were analysed using the Lexicomp database, and PDDIs between non-ARV and ARV drugs using the Liverpool drug interaction database. Between-group differences were assessed using c2, Mann-Whitney U and Kruskal-Wallis tests. Results: This analysis included 698 PLWH ≥50 years, 374 PLWH <50 years and 304 HIV-negative controls ≥50 years. The prevalence of polypharmacy was 65.8% in older PLWH, 48.1% in younger PLWH and 13.2% in the HIV-negative group. When ARVs were excluded, 29.8% of older PLWH and 14.2% of younger PLWH had polypharmacy. The prevalence of ≥1 PDDI involving non-ARV drugs was 36.1%, 20.3% and 16.4%, respectively, in older PLWH, younger PLWH and HIV-negative controls. In PLWH the prevalence of ≥1 PDDI involving ARV and non-ARV drugs was 57.3% in older PLWH and 32.4% in younger PLWH. Conclusions: Polypharmacy and PDDIs involving non-ARV/ ARV drugs and non-ARV/non-ARV drugs were common among older PLWH, highlighting the need for increased awareness and additional research on all types of PDDI.

Original languageEnglish
Pages (from-to)193-201
Number of pages9
JournalAntiviral Therapy
Volume24
Issue number3
DOIs
Publication statusPublished - 2019
Externally publishedYes

Fingerprint

Dive into the research topics of 'Polypharmacy and drug-drug interactions in older and younger people living with HIV: The POPPY study'. Together they form a unique fingerprint.

Cite this